Abstract
AbstractSince the 1980s, the MAO-B inhibitors have gained considerable status in the therapy of the Parkinson’s disease. In addition to the symptomatic effect in mono- and combination therapies, a neuroprotective effect has repeatedly been a matter of some discussion, which has unfortunately led to a good many misunderstandings. Due to potential interactions, selegiline has declined in significance in the field. For the MAO-B inhibitor safinamide, recently introduced to the market, an additional inhibition of pathological release of glutamate has been postulated. At present, rasagiline and selegiline are being administered in early therapy as well as in combination with levodopa. Safinamide has been approved only for combination therapy with levodopa when motor fluctuations have occurred. MAO-B inhibitors are a significant therapeutic option for Parkinson’s disease, an option which is too often not appreciated properly.
Funder
Universitätsklinikum des Saarlandes und Medizinische Fakultät der Universität des Saarlandes
Publisher
Springer Science and Business Media LLC
Subject
Biological Psychiatry,Psychiatry and Mental health,Neurology (clinical),Neurology
Reference117 articles.
1. Abbruzzese G, Kulisevsky J, Bergmans B, Gomez-Esteban JC, Kägi G, Raw J, Stefani A, Warnecke T, Jost WH, SYNAPSES Study Investigators Group (2021) A European observational study to evaluate the safety and the effectiveness of safinamide in routine clinical practice: The SYNAPSES Trial. J Parkinsons Dis 11(1):187–198. https://doi.org/10.3233/JPD-219007
2. Bali NR, Salve PS (2020) Impact of rasagiline nanoparticles on brain targeting efficiency via gellan gum based transdermal patch: a nanotheranostic perspective for Parkinsonism. Int J Biol Macromol 164:1006–1024. https://doi.org/10.1016/j.ijbiomac.2020.06.261
3. Bar Am O, Amit T, Youdim MBH (2004) Contrasting neuroprotective and neurotoxic actions of respective metabolites of anti-Parkinson drugs rasagiline and selegiline. Neurosci Lett 355:169–172. https://doi.org/10.1016/j.neulet.2003.10.067
4. Barone P, Santangelo G, Morgante L, Onofrj M, Meco G, Abbruzzese G, Bonuccelli U, Cossu G, Pezzoli G, Stanzione P, Lopiano L, Antonini A, Tinazzi M (2015) A randomized clinical trial to evaluate the effects of rasagiline on depressive symptoms in non-demented Parkinson’s disease patients. Eur J Neurol 22(8):1184–1191. https://doi.org/10.1111/ene.12724
5. Barone P, Fernandez HH, Ferreira J et al (2013) Safinamide as an add-on therapy to a stable dose of a single dopamine agonist: results from a randomized, placebo-controlled, 24-week multicenter trial in early idiopathic Parkinson disease (PD) patients (MOTION Study). Neurology 80 (Meeting Abstracts 1): P01.061
Cited by
30 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献